共 121 条
[1]
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries Cancer J Clin 71 209-49
[2]
Ferlay J(2016)Cancer statistics in China, 2015 Cancer J Clin 66 115-32
[3]
Siegel RL(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-21
[4]
Chen W(2009)Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666-73
[5]
Zheng R(2010)Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547-53
[6]
Baade PD(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991-7
[7]
Koizumi W(2019)A phase III study to compare the efficacy and safety of Paclitaxel Versus Irinotecan in patients with metastatic or recurrent gastric Cancer who failed in First-line therapy (KCSG ST10-01) Oncologist 24 18-e24
[8]
Narahara H(2012)Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 1513-8
[9]
Hara T(2011)Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2306-14
[10]
Kang YK(2013)Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial J Clin Oncol 31 4438-44